Drugs / 177Lu-LNC1011
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06250244 | May 2023 → Apr 2025 | castration-resistant prostate carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06809426 | Aug 2023 → Oct 2024 | castration-resistant prostate carcinoma | Affiliated Hospital of Jiangnan University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-LNC1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06250244 ↗ |
| Known as | [177Lu]Lu-LNC1011 | “Preclinical studies have shown that the long-acting PSMA-targeting radiopharmaceutical [177Lu]Lu-LNC1011 based on dansylated amino acid modification had high tumor uptake and...” PMID 40208314 ↗ Apr 2025 |
| Modality | Other / unclassified | “PSMA-targeted radioligand therapy” PMID 40208314 ↗ Apr 2025 |
| Route | Intravenous | “via intravenous injection” NCT06250244 ↗ |